Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer

被引:104
作者
Ejlertsen, Bent [9 ]
Jensen, Maj-Britt [6 ]
Rank, Fritz [8 ]
Rasmussen, Birgitte B. [5 ]
Christiansen, Peer [3 ]
Kroman, Niels [7 ]
Kvistgaard, Marianne E. [1 ]
Overgaard, Marie [2 ]
Toftdahl, Dorte B. [4 ]
Mouridsen, Henning T. [6 ]
机构
[1] Univ So Denmark, Odense Univ Hosp, Inst Clin Res, Dept Oncol, Odense, Denmark
[2] Aarhus Univ Hosp, Aarhus Sygehus, Dept Oncol, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Aarhus Sygehus, Unit Breast Surg, DK-8000 Aarhus, Denmark
[4] Copenhagen Univ Hosp, Roskilde Hosp, Dept Haematol & Oncol, DK-2100 Copenhagen, Denmark
[5] Copenhagen Univ Hosp, Herlev Hosp, Dept Pathol, DK-2100 Copenhagen, Denmark
[6] Copenhagen Univ Hosp, Rigshosp, DBCG Data Ctr, DK-2100 Copenhagen, Denmark
[7] Copenhagen Univ Hosp, Rigshosp, Dept Breast Surg, DK-2100 Copenhagen, Denmark
[8] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark
[9] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2009年 / 101卷 / 10期
关键词
BLOOD-VESSEL INVASION; NOTTINGHAM-PROGNOSTIC-INDEX; VASCULAR INVASION; ADJUVANT THERAPY; CARCINOMA; EXPERIENCE; CONSENSUS; EMBOLI;
D O I
10.1093/jnci/djp090
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Lymphovascular invasion has been associated with poor prognosis in women with breast cancer, but it is unclear whether the presence of lymphovascular invasion should be considered sufficient to reclassify breast cancer patients who are at a low risk of recurrence into a high-risk category. Of the 16 172 patients with operable breast cancer who were entered into the Danish Breast Cancer Cooperative Group Registry from January 1, 1996, to December 31, 2002, lymphovascular invasion was classified at primary diagnosis in 16 121 patients as present (n = 2453, 15%) or as absent (n = 13 206, 82%). Patients with at least one of the risk criteria (positive lymph nodes, tumor size > 2 cm, high grade, hormone receptor-negative tumor, or younger than 35 years) were assigned to the high-risk group; the other patients were assigned to the low-risk group. All procedures, including report forms, central review, and querying, were specified in advance. Kaplan-Meier analyses were used to estimate disease-free intervals and overall survival rates among patients with and without lymphovascular invasion, and multivariable analysis was used to adjust for differences in baseline characteristics and therapy. All statistical tests were two-sided. Complete follow-up was achieved for 15 659 patients. The median estimated potential follow-up was 6.4 years for invasive disease-free interval and 7.7 years for overall survival. Invasive disease-free interval and overall survival were statistically significantly associated with lymphovascular invasion within the high-risk group (hazard ratio [HR] for invasive disease = 2.29, 95% confidence interval [CI] = 2.14 to 2.45, P < .001; and HR for death = 2.42, 95% CI = 2.25 to 2.61, P < .001) but not within the low-risk group. At 5 years after surgery, 65.4% (95% CI = 63.5% to 67.3%) and 85.2% (95% CI = 84.5% to 85.9%) of those in the high-risk group with and without lymphovascular invasion were alive; 98.1% (95% CI = 87.6% to 99.7%) and 94.1% (95% CI = 93.2% to 94.8%) of those in the low-risk group with and without lymphovascular invasion were alive. These differences persisted in a multivariable analysis, and for overall survival, a statistically significant interaction (P = .03) was observed between lymphovascular invasion and risk group. In this prospective population-based study, lymphovascular invasion was not an independent high-risk criterion. Lymphovascular invasion should not by itself be considered sufficient to move patients from a low-risk group to a high-risk group.
引用
收藏
页码:729 / 735
页数:7
相关论文
共 29 条
[1]
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]
[Anonymous], 1982, AM J CLIN PATHOL, V78, P806, DOI DOI 10.1093/AJCP/78.6.806
[3]
THE NOTTINGHAM-PROGNOSTIC-INDEX APPLIED TO 9,149 PATIENTS FROM THE STUDIES OF THE DANISH-BREAST-CANCER-COOPERATIVE-GROUP (DBCG) [J].
BALSLEV, I ;
AXELSSON, CK ;
ZEDELER, K ;
RASMUSSEN, BB ;
CARSTENSEN, B ;
MOURIDSEN, HT .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (03) :281-290
[4]
Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer [J].
Colleoni, M. ;
Rotmensz, N. ;
Maisonneuve, P. ;
Sonzogni, A. ;
Pruneri, G. ;
Casadio, C. ;
Luini, A. ;
Veronesi, P. ;
Intra, M. ;
Galimberti, V. ;
Torrisi, R. ;
Andrighetto, S. ;
Ghisini, R. ;
Goldhirsch, A. . ;
Viale, G. .
ANNALS OF ONCOLOGY, 2007, 18 (10) :1632-1640
[5]
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].
Coombes, R. C. ;
Kilburn, L. S. ;
Snowdon, C. F. ;
Paridaens, R. ;
Coleman, R. E. ;
Jones, S. E. ;
Jassem, J. ;
Van de Velde, C. J. H. ;
Delozier, T. ;
Alvarez, I. ;
Del Mastro, L. ;
Ortmann, O. ;
Diedrich, K. ;
Coates, A. S. ;
Bajetta, E. ;
Holmberg, S. B. ;
Dodwell, D. ;
Mickiewicz, E. ;
Andersen, J. ;
Lonning, P. E. ;
Cocconi, G. ;
Forbes, J. ;
Castiglione, M. ;
Stuart, N. ;
Stewart, A. ;
Fallowfield, L. J. ;
Bertelli, G. ;
Hall, E. ;
Bogle, R. G. ;
Carpentieri, M. ;
Colajori, E. ;
Subar, M. ;
Ireland, E. ;
Bliss, J. M. .
LANCET, 2007, 369 (9561) :559-570
[6]
PROGNOSTIC-SIGNIFICANCE OF PERITUMORAL VESSEL INVASION IN CLINICAL-TRIALS OF ADJUVANT THERAPY FOR BREAST-CANCER WITH AXILLARY LYMPH-NODE METASTASIS [J].
DAVIS, BW ;
GELBER, R ;
GOLDHIRSCH, A ;
HARTMANN, WH ;
HOLLAWAY, L ;
RUSSELL, I ;
RUDENSTAM, CM .
HUMAN PATHOLOGY, 1985, 16 (12) :1212-1218
[7]
Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers [J].
de Mascarel, I ;
Bonichon, F ;
Durand, M ;
Mauriac, LH ;
MacGrogan, G ;
Soubeyran, I ;
Picot, V ;
Avril, A ;
Coindre, JM ;
Trojani, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (01) :58-65
[8]
Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979
[9]
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer [J].
Ejlertsen, Bent ;
Mouridsen, Henning T. ;
Jensen, Maj-Britt ;
Andersen, Jorn ;
Cold, Soren ;
Edlund, Per ;
Ewertz, Marianne ;
Jensen, Brita B. ;
Kamby, Claus ;
Nordenskjold, Bo ;
Bergh, Jonas .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) :877-884
[10]
Elston C W, 2002, Histopathology, V41, P154